Further Update - EpiPen® 300mcg adrenaline (epinephrine) autoinjectors supply delay - 23 Feb 2018

Mylan has advised that new stock of EpiPen® 300mcg adrenaline autoinjectors is now due to arrive by Friday 2 March and is expected to be available in pharmacies the following week. This will be followed by further new stock arriving soon afterwards. This has been updated since the previous notice that advised stock would be available by late February 2018. 

To ensure those at risk of anaphylaxis have access to the treatment they may need, supply should be restricted to patients with an EpiPen® prescription for a new diagnosis, or because their EpiPen® has expired or has recently been used.  We thank you in advance for your consideration of others at this challenging time.

We also request that schools and early childhood education and care (ECEC) centres take into account the current supply issues, by not requesting additional devices to be brought to the school or ECEC centre for each child at risk of anaphylaxis, and to limit the replacement of general use devices at this time. 

It is important to note that currently there is no shortage of EpiPen® Jr 150mcg adrenaline autoinjectors. If a pharmacy is out of stock of EpiPen® Jr, the pharmacist should contact their wholesaler/s to obtain stock. If there are any problems they should phone Mylan on 1800 274 276.

A process has been put in place by Mylan to ensure those at risk of anaphylaxis have access to the treatment they may need. Patients requiring an EpiPen® 300mcg autoinjector should go to their local pharmacy.  If that pharmacy does not have stock then the pharmacist should then contact Mylan (phone 1800 274 276 or email This email address is being protected from spambots. You need JavaScript enabled to view it.) to obtain instructions on how to access emergency supply.  

Individuals will be able to access one in-date adrenaline autoinjector until the shortage resolves by early March 2018.  It is important to note that a device expiring in March 2018 does not actually expire until the end of that month, not the start of that month. Patients should retain their recently expired autoinjector/s (see information below).

In the case of anaphylaxis, patients and/or carers should follow instructions on their ASCIA Action Plan www.allergy.org.au/anaphylaxis (Give EpiPen® and call an ambulance by phoning 000). 

Patients and/or carers who require support should contact the national patient support organisations, Allergy & Anaphylaxis Australia (phone 1300 728 000 or contact us).

Use of expired adrenaline autoinjectors

Whilst the use of an expired adrenaline autoinjector is not ideal, research suggests that recently expired devices retain potency. Therefore, if no other adrenaline autoinjector is available, use of a recently expired device to treat anaphylaxis is advised, as stated on the ASCIA website: 


Acute Anaphylaxis CSS
Acute Anaphylaxis Clinical Care Standard - Learn more...
Atopic Dermatitis
allergy250K teens/young adults
Food allergy training

Our Supporters


Allergy Concepts


  • Bulla
  • NSW Food Authority
  • Novartis
  • Pfizer


  • dbv technologies
  • Mondelez
  • Nurticia

  • abbvie
  • Australian Camps Association
  • Bayer
  • Sanctuary Early Learning
  • Sweet William

ABN: 70 693 242 620


is supported by funding from the
Australian Government,
Department of Health.

ALLERGY & ANAPHYLAXIS AUSTRALIA acknowledges and pays respect to the traditional custodians of the lands on which we work, live and play.


If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.